| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 83.23 | 2602.3% |
| Total Income | 83.23 | 2602.3% |
| Expenditure | 79.35 | 27.8% |
| PBT | 5.40 | 110.1% |
| Net Profit | 5.40 | 110.1% |
| OPM | 4.66% | |
| NPM | 6.49% | |
| EPS | 0.02 | 112.5% |
Nuvation Bio Reports Q1 2026 Financial Results; IBTROZI Net Revenue $18.5M
05 May 2026 · 5 May, 1:57 am
Summary
Nuvation Bio reported financial results for the first quarter ended March 31, 2026. The company achieved $18.5 million in net product revenues for IBTROZI. Collaboration and license agreements revenue increased to $64.7 million, primarily due to the Eisai agreement. Nuvation Bio also announced the acquisition of Japan rights to safusidenib. The company's cash, cash equivalents, and marketable securities totaled $533.7 million as of March 31, 2026, and net income was $5.4 million.
Key Highlights
- 1
Nuvation Bio achieved $18.5 million in net product revenues for IBTROZI® in the first quarter of 2026.
- 2
Approximately 200 patients started on IBTROZI in Q1 2026, with the majority being TKI-naïve.
- 3
Updated clinical data presented at AACR 2026 demonstrated IBTROZI’s durability of response and progression-free survival in TKI-naïve and TKI-pretreated patients.
- 4
Nuvation Bio announced the acquisition of Japan rights to safusidenib from Daiichi Sankyo.
- 5
The company reported cash, cash equivalents, and marketable securities of $533.7 million as of March 31, 2026.
- 6
Collaboration and license agreements revenue was $64.7 million for the three months ended March 31, 2026, compared to $3.1 million for the three months ended March 31, 2025.
- 7
Nuvation Bio reported a net income of $5.4 million, or $0.02 per share on a basic basis and $0.01 per share on a diluted basis for the three months ended March 31, 2026.
Management Comments
David Hung
M.D.
We are pleased with IBTROZI’s ongoing launch trends in the first quarter of 2026, as we continue to deepen its adoption across lines of therapy and make significant progress in becoming the standard of care for people living with advanced ROS1-positive NSCLC. The newly updated long-term follow-up data from our pivotal studies presented at AACR demonstrated an unprecedented durability for IBTROZI of now more than four years in TKI-naïve patients, further supporting healthcare providers and their patients’ confidence in selecting IBTROZI. With our partners, we are well on our way to bringing this important medicine to patients in need around the world. We are also thrilled to have secured exclusive global development and commercialization rights to safusidenib. We look forward to advancing the pivotal Phase 3 SIGMA study for patients with high-risk IDH1-mutant glioma, where targeted treatment options are incredibly limited. Additionally, we are well on track to provide updates on our drug-drug conjugate platform later this year as we further our mission to tackle some of the toughest challenges in cancer treatment.”
Informational and educational content only. Not investment advice.